The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. The week’s IPOs were joined by 24 SPACs that raised $8.4 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings. ...read more
Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, raised $40 million by offering 3.6 million shares at $11, within the range of $10 to $12. At pricing, the company commands a fully diluted market value...read more
Updated Monday, 3/15. The IPO market starts to pick back up with 10 IPOs scheduled to raise $2.5 billion in the week ahead. Chinese IoT platform developer Tuya (TUYA) plans to raise $806 million at a $10.4 billion market...read more
Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, announced terms for its IPO on Wednesday.
The Bethesda, MD-based company plans to raise $40 million by offering 3.6 million shares at a price range...read more
US IPO Weekly Recap: The IPO market heats up in an 11 IPO week
The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. The week’s IPOs were joined by 24 SPACs that raised $8.4 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings. ...read more
Lysosomal storage disorder biotech Gain Therapeutics prices IPO at $11 midpoint
Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, raised $40 million by offering 3.6 million shares at $11, within the range of $10 to $12. At pricing, the company commands a fully diluted market value...read more
US IPO Week Ahead: The spring IPO Market starts to thaw in a 10 IPO week
Updated Monday, 3/15. The IPO market starts to pick back up with 10 IPOs scheduled to raise $2.5 billion in the week ahead. Chinese IoT platform developer Tuya (TUYA) plans to raise $806 million at a $10.4 billion market...read more
Lysosomal storage disorder biotech Gain Therapeutics sets terms for $40 million IPO
Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, announced terms for its IPO on Wednesday. The Bethesda, MD-based company plans to raise $40 million by offering 3.6 million shares at a price range...read more